OOIR: Observatory of International Research

Papers

(The TQCC of British Journal of Dermatology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Classification of the cutaneous manifestations of COVID ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases	926
SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases	335
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*	280
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*	210
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*	180
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases	176
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial	173
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases	162
Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue	157
The global burden of chronic urticaria for the patient and society*	154
Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions	133
Role of regulatory T cells in psoriasis pathogenesis and treatment	127
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update	123
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical	119
The epidemiology of hidradenitis suppurativa*	106
Aetiology and pathogenesis of hidradenitis suppurativa	94
The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience	91
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)	89
Co‐reactivation of the human herpesvirus alpha subfamily (herpes simplex virus‐1 and varicella zoster virus) in a critically ill patient with COVID‐19	74
The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case series	73
Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis	73
Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*	69
Reviewing the global burden of acne: how could we improve care to reduce the burden?*	69
Absence of images of skin of colour in publications of COVID‐19 skin manifestations	69
Cutaneous lesions in a patient with COVID‐19: are they related?	60

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*	60
Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*	60
Exploring the human hair follicle microbiome*	59
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings	58
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURF	57
Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic	56
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*	55
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*	54
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis	53
COVID‐19 chilblain‐like lesion: immunohistochemical demonstration of SARS‐CoV‐2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction‐negative patient	53
Putting the burden of skin diseases on the global map	51
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label	51
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent	49
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*	48
Applications and future directions for optical coherence tomography in dermatology*	48
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III,	46
British Association of Dermatologists guidelines for the management of people with vitiligo 2021	45
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*	45
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studi	45
Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*	44
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial	44
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*	43
Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID ‐19	43
Activity and components of the granulocyte colony‐stimulating factor pathway in hidradenitis suppurativa*	43
Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials	43
A narrative review of the epidemiology and economics of chronic wounds	42
Prevalence, pathophysiology and management of itch in epidermolysis bullosa*	42
Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*	42
Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*	42
Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*	41
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*	41
Global evidence on occupational sun exposure and keratinocyte cancers: a systematic review	41
Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*	39
Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies*	38
The biological basis of disease recurrence in psoriasis: a historical perspective and current models	38
Tape strips in dermatology research*	37
The epidemiology of alopecia areata: a population‐based cohort study in UK primary care*	37
Ultraviolet A radiation and COVID‐19 deaths in the USA with replication studies in England and Italy*	37
Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors	36
Clinical, dermoscopic and histopathological findings in localized human monkeypox: a case from northern Italy	36
Ex vivo confocal microscopy: revolution in fast pathology in dermatology	36
Challenges in the diagnosis and management of wound infection	35
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*	35
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study*	35
WNT10A , dermatology and dentistry	35
A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris	34
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing	33
COVID‐19‐related dermatosis in November 2019: could this case be Italy’s patient zero?	33
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial	33
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclos	33

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up	32
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid*	32
Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019*	32
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*	32
Cellulitis in chronic oedema of the lower leg: an international cross‐sectional study	31
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)	31
Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragm	31
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb	30
Equity in skin typing: why it is time to replace the Fitzpatrick scale	30
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five ye	30
Therapeutic potential of targeting interleukin‐1 family cytokines in chronic inflammatory skin diseases*	30
Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease	30
Weekly administration of brodalumab in hidradenitis suppurativa: an open‐label cohort study	30
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual	30
Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum	29
High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*	29
Prevalence and incidence of generalized pustular psoriasis in Sweden: a population‐based register study*	29
The associated burden of mental health conditions in alopecia areata: a population‐based study in UK primary care*	29
No evidence of SARS‐CoV‐2 infection by polymerase chain reaction or serology in children with pseudo‐chilblain	28
Body dysmorphia in common skin diseases: results of an observational, cross‐sectional multicentre study among dermatological outpatients in 17 European countries*	28
The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*	28
Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways	28
Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone skin*	28
Association between atopic dermatitis and autoimmune diseases: a population‐based case–control study*	27
Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies	27
	27
Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated	27
Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study	27
Response to ‘Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases’: vesicular eruption in COVID‐19 – to exclude varicella	27
Early melanoma invasivity correlates with gut fungal and bacterial profiles	27
Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink*	26
Measurement properties of the Patient‐Reported Outcomes Information System (PROMIS^®) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis*	26
SARS‐CoV‐2 spike protein positivity in pityriasis rosea‐like and urticaria‐like rashes of COVID‐19	26
Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized byde novointerleukin‐17A expression: a case report	26
The global incidence of bullous pemphigoid: a systematic review and meta‐analysis	26
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials	25
The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study	25
Melanoma pathology: new approaches and classification*	25
Phototherapeutic approach to dermatology patients during the 2019 coronavirus pandemic: real‐life data from the Italian red zone	25
Pernio after COVID‐19 vaccination	25
Minimal, superficial DNA damage in human skin from filtered far‐ultraviolet C	25
Opsin 5 is a key regulator of ultraviolet radiation‐induced melanogenesis in human epidermal melanocytes*	24
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre st	24
Occupational dermatoses during the COVID‐19 pandemic: a multicentre audit in the UK and Ireland	24
The effect of screening on melanoma incidence and biopsy rates	24
Topical preparations for the treatment of mild‐to‐moderate acne vulgaris: systematic review and network meta‐analysis*	24
Biomarkers of disease progression in people with psoriasis: a scoping review	24
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study	24
Increased expression of interleukin‐23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment	24
The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database*	23
Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus	23
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials	23
	23
Upregulated E3 ligase tripartite motif‐containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor‐κB p65 subunit and promotes inflammation in keratinocytes*	23
British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021*	23
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*	22
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials	22
A clinical and biological review of keratoacanthoma*	22
A 10‐year review of surgical management of dermatofibrosarcoma protuberans*	22
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata	22
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*	22
Oral vesiculobullous lesions as an early sign of COVID‐19: immunohistochemical detection of SARS‐CoV‐2 spike protein	22
Atopic eczema and obesity: a population‐based study*	22
Pityriasis rosea‐like eruption after Pfizer–BioNTech COVID‐19 vaccination	22
Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*	21
A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*	21
Randomized controlled trial of topical corticosteroid and home‐based narrowband ultraviolet B for active and limited vitiligo: results of the HI‐Light Vitiligo Trial*	21
Air pollution‐induced tanning of human skin*	21
Bacterial and fungal microbiome characterization in patients with rosacea and healthy controls	21
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study	21
Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study*	21
Association between air pollution and atopic dermatitis in Guangzhou, China: modification by age and season*	21
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis	21
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study	21
Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data	21
The Eumelanin Human Skin Colour Scale: a proof‐of‐concept study	20
Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*	20
Identification of proteins associated with development of metastasis from cutaneous squamous cell carcinomas (cSCCs) via proteomic analysis of primary cSCCs*	20
British Association of Dermatologists guidelines for the management of people with rosacea 2021*	20
A guideline for the clinical management of basal cell naevus syndrome (Gorlin–Goltz syndrome)*	20

Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data*	20
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherap	20
Estimating the global burden of scabies: what else do we need?*	20
Doppler ultrasound‐based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity	20
Total body photography for the diagnosis of cutaneous melanoma in adults: a systematic review and meta‐analysis*	20
Ca ²⁺ signalling is critical for autoantibody‐induced blistering of human epidermis in pemphigus*	20
A decade of next‐generation sequencing in genodermatoses: the impact on gene discovery and clinical diagnostics*	20
Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis	20
Diagnostic and therapeutic differences between immune checkpoint inhibitor‐induced and idiopathic bullous pemphigoid: a cross‐sectional study	20
New insights in hidradenitis suppurativa from a population‐based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities*	19
Evidence of gene–gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins	19
Efficacy and safety of topical resorcinol 15% as long‐term treatment of mild‐to‐moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance	19
Mutations in genes encoding desmosomal proteins: spectrum of cutaneous and extracutaneous abnormalities*	19
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect	19
Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial–mesenchymal transition	19
Meta‐analysis results do not reflect the real safety of biologics in psoriasis*	19
A monkeypox virus infection mimicking primary syphilis	19
Silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy to prevent hospital‐acquired pressure ulcers: a pragmatic noncommercial multicentre randomized open‐label parallel‐group me	19
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series	19
Risk of skin cancer in new users of thiazides and thiazide‐like diuretics: a cohort study using an active comparator group*	19
The long noncoding RNA MALAT1 suppresses miR‐211 to confer protection from ultraviolet‐mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1*	19
HSP90 inhibitor RGRN‐305 for oral treatment of plaque‐type psoriasis: efficacy, safety and biomarker results in an open‐label proof‐of‐concept study*	19
British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021	19
Chilblain lesions after COVID‐19 mRNA vaccine	19
Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis	19
Primary cutaneous anaplastic large‐cell lymphoma with marked spontaneous regression of organ manifestation after SARS‐CoV‐2 vaccination	19
Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population‐based cohort study*	18
Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*	18
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study	18
Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota*	18
A novel personalized treatment approach for psoriasis: anti‐vascular endothelial growth factor‐A (VEGF‐A) therapy	18
New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP₃‐R, ACTH, MC‐R2)	18
Hailey–Hailey disease treated with dupilumab: a case series	18
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*	18
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermato	18
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial	18
Dimethyl fumarate modulates the Treg–Th17 cell axis in patients with psoriasis*	18
Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients	18
Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3)	17
Chronic prurigo	17
Accuracy of commercially available smartphone applications for the detection of melanoma	17
Chilblains and COVID‐19: why SARS‐CoV‐2 endothelial infection is questioned	17
Relationship between atopic dermatitis, depression and anxiety: a two‐sample Mendelian randomization study	17
Views on mobile health apps for skin cancer screening in the general population: an in‐depth qualitative exploration of perceived barriers and facilitators*	17
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)	17
Novel nicastrin mutation in hidradenitis suppurativa–Dowling–Degos disease clinical phenotype: more than just clinical overlap?	17
Aetiology of tinea capitis in China: a multicentre prospective study	17
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha	17
Mortality and clinical response of patients with bullous pemphigoid treated with rituximab	17
Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort	17
COVID‐19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision	17
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population	17
Outcomes for Pressure Ulcer Trials (OUTPUTs) project: review and classification of outcomes reported in pressure ulcer prevention research	17
Clinical photography in skin of colour: tips and best practices	17
The impact of the COVID‐19 pandemic on skin cancer incidence and treatment in England, 2020	16
	16
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab	16
Inflammatory skin diseases and the risk of chronic kidney disease: population‐based case–control and cohort analyses*	16
Hidradenitis Suppurativa Area and Severity Index Revised (HASI‐R): psychometric property assessment*	16
Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based	16
Biopsy outperforms reflectance confocal microscopy in diagnosing and subtyping basal cell carcinoma: results and experiences from a randomized controlled multicentre trial*	16
Omalizumab for the treatment of chronic inducible urticaria in 80 patients	16
Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*	16
Enhanced expression of angiotensin‐converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon‐γ: implication of inflammatory milieu in skin tropism of SARS‐CoV‐2	16
Limited impact of COVID ‐19‐related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analys	16
Occupational dermatology in the time of the COVID‐19 pandemic: a report of experience from London and Manchester, UK	16
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*	16
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers	16
Clinical and immunological findings in 55 patients with anti‐laminin 332‐type mucous membrane pemphigoid	16
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study	16
Development of a condition‐specific patient‐reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire	16
A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI‐Relevant and Skindex‐16*	15
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis	15
Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology	15
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*	15
17th Medical Dermatology Meeting, 13 January 2022	15
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies	15
Large‐scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*	15
Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature*	15
Perceived psychological stress and risk of herpes zoster: a nationwide population‐based cohort study*	15
Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*	15
Lesional activation of T _c 17 cells in Behçet disease and psoriasis supports HLA class I‐mediated autoimmune responses*	15
Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department	15
Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy*	15
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids:	15
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils	15
Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies	15
Low‐dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome	15
Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app	15
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*	15
The promise and challenges of cell therapy for psoriasis*	15
Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020	15
Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity*	15
Identification of clonal skin myeloid cells by next‐generation sequencing in myelodysplasia cutis	14
Inflammatory skin diseases and wounds	14